Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Scleroderma-like cutaneous syndromes.

Yasuji Mori1, Veli-Matti Kahari, John Varga

  • 1Section of Rheumatology, University of Illinois at Chicago College of Medicine, 1158 MBRB, 900 S. Ashland Avenue, Chicago, IL 60607-7171, USA. jvarga@uic.edu

Current Rheumatology Reports
|March 14, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multicytokine-based transcriptome-wide association study for 7 inflammatory skin disorders identifies candidate causal genes in keratinocytes.

The Journal of allergy and clinical immunology·2026
Same author

Imbalance of Ciliary Programs Drives Fibroblast Differentiation and Fibrotic Signaling in Systemic Sclerosis.

bioRxiv : the preprint server for biology·2026
Same author

Aurora A kinase activation contributes to the fibrotic phenotype in systemic sclerosis through primary cilia shortening.

Arthritis research & therapy·2026
Same author

Nintedanib attenuates profibrotic gene expression in a 3-dimensional organotypic culture model of systemic sclerosis skin fibrosis.

The Journal of investigative dermatology·2026
Same author

C1s protects cutaneous squamous carcinoma cells from TRAIL-induced apoptosis.

Oncogenesis·2026
Same author

A potent inhibitor of PAI-1, MDI-2517, mitigates disease severity in a preclinical systemic sclerosis model.

JCI insight·2026
Same journal

Type I Interferonopathies: Fifteen Years On, From Concept to Therapeutic Perspectives.

Current rheumatology reports·2026
Same journal

Intensive Care Management of ANCA-associated Vasculitides: a Narrative Review.

Current rheumatology reports·2026
Same journal

The Role of Musculoskeletal Ultrasound in Psoriatic Arthritis: From Preclinical Detection to Treatment Monitoring.

Current rheumatology reports·2026
Same journal

Correction to: Is Gout and Autoinflammatory Disease?

Current rheumatology reports·2026
Same journal

Risks and Management of Glucocorticoid Therapy for Patients with Rheumatic Disease Having Surgery.

Current rheumatology reports·2026
Same journal

Perioperative Management Considerations for Patients with Systemic Lupus Erythematosus.

Current rheumatology reports·2026
See all related articles

Scleroderma-like conditions, including eosinophilic fasciitis and drug-induced pseudosclerodermas, mimic systemic sclerosis. Accurate diagnosis is crucial for appropriate treatment, as these disorders share similar fibrotic pathways.

Area of Science:

  • Dermatology
  • Rheumatology
  • Pathophysiology

Background:

  • Dermal fibrosis encompasses conditions that mimic scleroderma/systemic sclerosis.
  • Scleroderma-like conditions include eosinophilic fasciitis, localized scleroderma, scleredema, scleromyxedema, keloids, eosinophilia-myalgia syndrome, and drug-induced pseudosclerodermas.
  • Accurate recognition of these uncommon disorders is vital to prevent misdiagnosis and incorrect treatment.

Purpose of the Study:

  • To review and synthesize current understanding of scleroderma-like disorders.
  • To highlight shared pathogenetic mechanisms with scleroderma.
  • To discuss emerging research and treatment considerations.

Main Methods:

  • Literature review of epidemiologic investigations.

Related Experiment Videos

  • Analysis of in vivo and in vitro experimental research findings.
  • Synthesis of data on fibroblast activity, cytokine involvement, and potential etiologies.

    • Main Results:

    • Recurrent findings include eosinophil activation and dysregulated fibroblast collagen synthesis, apoptosis, and proliferation.
    • Cytokines like transforming growth factor-beta, interleukin-4, -13, and connective tissue growth factor contribute to fibrosis.
    • The role of microbial infections is debated, and genetic factors require further investigation.

    Conclusions:

    • Scleroderma-like disorders share pathogenetic similarities with scleroderma, involving fibroblast and cytokine dysregulation.
    • Limited clinical trials exist due to rarity, with no consensus on optimal management.
    • Phototherapy shows potential in treating these fibrotic conditions based on anecdotal evidence and small series.